ONLINE COVER Heating Up Tumors. This image shows co-expression (yellow) of the oncoprotein Tribbles homolog 3 (TRIB3, green) and the acetyltransferase P300 (red) in tumor tissue from a patient with colorectal cancer. Nuclei are shown in blue. Converting immune "cold" tumors that have poor T cell infiltration to highly infiltrated, immune "hot" tumors is a promising strategy to improve outcomes for colorectal cancer. Shang et al. demonstrated that TRIB3 inhibited CD8+ T cell infiltration into colorectal tumors by reducing CXCL10 production. P300-mediated acetylation stabilized TRIB3 protein, which could be reversed by treating colorectal cancer tumor-bearing mice with a P300 inhibitor. Treatment increased CD8+ T cell infiltration into tumors and sensitized them to immune checkpoint blockade, suggesting that TRIB3 may be a useful target for colorectal cancer.
Credit: Shang et al./Science Translational MedicineScience Translational Medicine
- Volume 14|
- Issue 626|
- 5 Jan 2022
ONLINE COVER Heating Up Tumors. This image shows co-expression (yellow) of the oncoprotein Tribbles homolog 3 (TRIB3, green) and the acetyltransferase P300 (red) in tumor tissue from a patient with colorectal cancer. Nuclei are shown in blue. Converting immune "cold" tumors that have poor T cell infiltration to highly infiltrated, immune "hot" tumors is a promising strategy to improve outcomes for colorectal cancer. Shang et al. demonstrated that TRIB3 inhibited CD8+ T cell infiltration into colorectal tumors by reducing CXCL10 production. P300-mediated acetylation stabilized TRIB3 protein, which could be reversed by treating colorectal cancer tumor-bearing mice with a P300 inhibitor. Treatment increased CD8+ T cell infiltration into tumors and sensitized them to immune checkpoint blockade, suggesting that TRIB3 may be a useful target for colorectal cancer.
Credit: Shang et al./Science Translational Medicine
